סיקור מלא· בריאות· עודכן
FDA Approves Revolutionary Pancreatic Cancer Drug Boosting Revolution Medicines' Valuation
The FDA approved Rasonque, a new drug by Revolution Medicines, for metastatic pancreatic cancer, doubling patient survival and boosting the company’s valuation to $46 billion. The drug uniquely targets the RAS protein and showed unprecedented clinical results, leading to early approval.
6 מערכות · שפה אחת · מאז
Plus
מה קרה
- 01FDA approves Rasonque for metastatic pancreatic cancer, doubling patient survival to 13.2 months.
- 02Revolution Medicines’ stock surged 477% in a year, valuing the company at $46 billion.
- 03Rasonque targets the RAS protein, a key driver in 90%-95% of pancreatic cancers.
- 04The drug was approved based on a 500-patient trial with fewer side effects than chemotherapy.
- 05Merck’s $28-$32 billion acquisition attempt of Revolution Medicines failed over pricing.
- 06Other pharma giants and Israeli firms are developing RAS-targeting cancer therapies.
Revolution Medicines is exploring broader uses and faces competition from major pharma firms developing similar therapies.
הסיקור
6 מערכות על הידיעה
מי סיקר
- שמאלאין
- מרכז2
- ימין2
- חרדית1
- ערביתאין
- אחרים1
איך הידיעה התפרסמה
ראו מי מבין 6 המערכות פרסם ראשון, ומי חיכה